We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alexion Pharmaceuticals Inc | NASDAQ:ALXN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 182.50 | 183.00 | 185.00 | 0 | 01:00:00 |
From May 2021 to May 2024
By Adria Calatayud
The U.K. Competition and Markets Authority said Wednesday that it won't refer AstraZeneca PLC's anticipated acquisition of Alexion Pharmaceuticals Inc. for further review.
The antitrust watchdog said it has decided not to refer the deal for an in-depth review based on the information currently available to it.
Earlier this month, the Cambridge-U.K.-based pharmaceutical company said it had received clearance from the European Union for its purchase of Alexion. AstraZeneca previously said it expected to close the deal in the third quarter.
AstraZeneca in December agreed to acquire Boston-based Alexion for $39 billion in cash and stock to expand its offering of treatments for rare diseases.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
July 14, 2021 02:24 ET (06:24 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Alexion Pharmaceuticals Chart |
1 Month Alexion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
